Skip to main content

Advertisement

SpringerLink
Log in

Biologic agents in experimental autoimmune uveitis

  • Review
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Experimental uveitis models were developed in an effort to elucidate the pathogenesis of human uveitis. The therapeutic effects of numerous anti-inflammatory agents including corticosteroids and immunomodulatory agents including biologic response modifiers have been investigated in both experimental and human uveitis. Monoclonal antibodies to tumor necrosis factor alpha and anti-interleukins, among others, demonstrate efficacy and are employed in the treatment of uveitis refractory to conventional immunomodulatory agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130(4):492–513

    CAS  PubMed  Google Scholar 

  2. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516

    PubMed  Google Scholar 

  3. Bloch-Michel E, Nussenblatt RB (1987) International uveitis study group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 103(2):234–235

    CAS  PubMed  Google Scholar 

  4. Cervantes-Castaneda RA, Giuliari GP, Gallagher MJ, Yilmaz T, MacDonell RE, Quinones K et al (2009) Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol 19(4):622–629

    PubMed  Google Scholar 

  5. Wakefield D, Dunlop I, McCluskey PJ, Penny R (1986) Uveitis: aetiology and disease associations in an Australian population. Aust N Z J Ophthalmol 14(3):181–187

    CAS  PubMed  Google Scholar 

  6. Shao H, Lei S, Sun SL, Kaplan HJ, Sun D (2003) Conversion of monophasic to recurrent autoimmune disease by autoreactive T cell subsets. J Immunol 171(10):5624–5630

    CAS  PubMed  Google Scholar 

  7. Shao H, Shi H, Kaplan HJ, Sun D (2005) Chronic recurrent autoimmune uveitis with progressive photoreceptor damage induced in rats by transfer of IRBP-specific T cells. J Neuroimmunol 163(1–2):102–109

    CAS  PubMed  Google Scholar 

  8. Shao H, Liao T, Ke Y, Shi H, Kaplan HJ, Sun D (2006) Severe chronic experimental autoimmune uveitis (EAU) of the C57BL/6 mouse induced by adoptive transfer of IRBP1-20-specific T cells. Exp Eye Res 82(2):323–331

    CAS  PubMed  Google Scholar 

  9. Posarelli C, Arapi I, Figus M, Neri P (2011) Biologic agents in inflammatory eye disease. J Ophthalmic Vis Res 6(4):309–316

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Michalova K, Lim L (2008) Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep 8(4):339–347

    CAS  PubMed  Google Scholar 

  11. Okada AA (2010) The dream of biologics in uveitis. Arch Ophthalmol 128(5):632–635

    PubMed  Google Scholar 

  12. Servat JJ, Mears KA, Black EH, Huang JJ (2012) Biological agents for the treatment of uveitis. Expert Opin Biol Ther 12(3):311–328

    CAS  PubMed  Google Scholar 

  13. Zakka FR, Chang PY, Giuliari GP, Foster CS (2009) Current trends in the management of ocular symptoms in Adamantiades-Behcet’s disease. Clin Ophthalmol 3:567–579

    PubMed Central  PubMed  Google Scholar 

  14. Imrie FR, Dick AD (2007) Biologics in the treatment of uveitis. Curr Opin Ophthalmol 18(6):481–486

    PubMed  Google Scholar 

  15. Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ, BIOGEAS STUDY Group (2008) A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87(6):345–364

    Google Scholar 

  16. Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M, BIOGEAS study group (2012) Biologics-induced autoimmune diseases. Curr Opin Rheumatol. doi:10.1097/BOR.0b013e32835b1366

    Google Scholar 

  17. Faure JP (1980) Autoimmunity and the retina. Curr Top Eye Res 2:215–302

    CAS  PubMed  Google Scholar 

  18. Caspi RR, Roberge FG, Chan CC, Wiggert B, Chader GJ, Rozenszajn LA et al (1988) A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 140(5):1490–1495

    CAS  PubMed  Google Scholar 

  19. Agarwal RK, Silver PB, Caspi RR (2012) Rodent models of experimental autoimmune uveitis. Methods Mol Biol 900:443–469

    CAS  PubMed  Google Scholar 

  20. Luger D, Caspi RR (2008) New perspectives on effector mechanisms in uveitis. Semin Immunopathol 30(2):135–143

    PubMed Central  PubMed  Google Scholar 

  21. Lee DJ, Biros DJ, Taylor AW (2009) Injection of an alpha-melanocyte stimulating hormone expression plasmid is effective in suppressing experimental autoimmune uveitis. Int Immunopharmacol 9(9):1079–1086

    CAS  PubMed Central  PubMed  Google Scholar 

  22. Broekhuyse RM, Kuhlmann ED, Winkens HJ (1992) Experimental autoimmune anterior uveitis (EAAU). II. Dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium. Exp Eye Res 55(3):401–411

    CAS  PubMed  Google Scholar 

  23. Bora NS, Kim MC, Kabeer NH, Simpson SC, Tandhasetti MT, Cirrito TP et al (1995) Experimental autoimmune anterior uveitis. Induction with melanin-associated antigen from the iris and ciliary body. Invest Ophthalmol Vis Sci 36(6):1056–1066

    CAS  PubMed  Google Scholar 

  24. Matteson DM, Shen DF, Chan CC (1999) Inhibition of experimental melanin protein-induced uveitis (EMIU) by targeting nitric oxide via phosphatidylcholine-specific phospholipase C. J Autoimmun 13(2):197–204

    CAS  PubMed  Google Scholar 

  25. Kim MC, Kabeer NH, Tandhasetti MT, Kaplan HJ, Bora NS (1995) Immunohistochemical studies on melanin associated antigen (MAA) induced experimental autoimmune anterior uveitis (EAAU). Curr Eye Res 14(8):703–710

    CAS  PubMed  Google Scholar 

  26. Buenafe AC, Offner H, Machnicki M, Elerding H, Adlard K, Jacobs R et al (1998) EAE TCR motifs and antigen recognition in myelin basic protein-induced anterior uveitis in Lewis rats. J Immunol 161(4):2052–2059

    CAS  PubMed  Google Scholar 

  27. Adamus G, Chan CC (2002) Experimental autoimmune uveitides: multiple antigens, diverse diseases. Int Rev Immunol 21(2–3):209–229

    CAS  PubMed  Google Scholar 

  28. Adamus G, Sugden B, Arendt A, Hargrave PA (2001) Importance of cryptic myelin basic protein epitopes in the pathogenicity of acute and recurrent anterior uveitis associated with EAE. J Neuroimmunol 113(2):212–219

    CAS  PubMed  Google Scholar 

  29. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR (1980) Endotoxin-induced uveitis in rats as a model for human disease. Nature 286(5773):611–613

    CAS  PubMed  Google Scholar 

  30. Bhattacherjee P, Parke A (1986) The reduction of inflammatory responses in lipopolysaccharide-tolerant eyes. Am J Pathol 122(2):268–276

    CAS  PubMed  Google Scholar 

  31. Smith JR, Hart PH, Williams KA (1998) Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol Cell Biol 76(6):497–512

    CAS  PubMed  Google Scholar 

  32. McMenamin PG, Crewe J (1995) Endotoxin-induced uveitis. Kinetics and phenotype of the inflammatory cell infiltrate and the response of the resident tissue macrophages and dendritic cells in the iris and ciliary body. Invest Ophthalmol Vis Sci 36(10):1949–1959

    CAS  PubMed  Google Scholar 

  33. Yang P, de Vos AF, Kijlstra A (1996) Macrophages in the retina of normal Lewis rats and their dynamics after injection of lipopolysaccharide. Invest Ophthalmol Vis Sci 37(1):77–85

    CAS  PubMed  Google Scholar 

  34. McMenamin PG, Crewe J, Morrison S, Holt PG (1994) Immunomorphologic studies of macrophages and MHC class II-positive dendritic cells in the iris and ciliary body of the rat, mouse, and human eye. Invest Ophthalmol Vis Sci 35(8):3234–3250

    CAS  PubMed  Google Scholar 

  35. Fleisher LN, Ferrell JB, McGahan MC (1992) Synergistic uveitic effects of tumor necrosis factor-alpha and interleukin-1 beta. Invest Ophthalmol Vis Sci 33(7):2120–2127

    CAS  PubMed  Google Scholar 

  36. Hoekzema R, Verhagen C, van Haren M, Kijlstra A (1992) Endotoxin-induced uveitis in the rat. The significance of intraocular interleukin-6. Invest Ophthalmol Vis Sci 33(3):532–539

    CAS  PubMed  Google Scholar 

  37. de Kozak Y, Sakai J, Thillaye B, Faure JP (1981) S antigen-induced experimental autoimmune uveo-retinitis in rats. Curr Eye Res 1(6):327–337

    PubMed  Google Scholar 

  38. Gery I, Wiggert B, Redmond TM, Kuwabara T, Crawford MA, Vistica BP et al (1986) Uveoretinitis and pinealitis induced by immunization with interphotoreceptor retinoid-binding protein. Invest Ophthalmol Vis Sci 27(8):1296–1300

    CAS  PubMed  Google Scholar 

  39. Caspi RR (1999) Immune mechanisms in uveitis. Springer Semin Immunopathol 21(2):113–124

    CAS  PubMed  Google Scholar 

  40. Caspi RR (1992) Immunogenetic aspects of clinical and experimental uveitis. Reg Immunol 4(5):321–330

    CAS  PubMed  Google Scholar 

  41. Dullforce PA, Seitz GW, Garman KL, Michael JA, Crespo SM, Fleischman RJ et al (2006) Antigen-specific accumulation of naive, memory and effector CD4 T cells during anterior uveitis monitored by intravital microscopy. Cell Immunol 239(1):49–60

    CAS  PubMed  Google Scholar 

  42. Caspi RR (2002) Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol 21(2–3):197–208

    CAS  PubMed  Google Scholar 

  43. Caspi RR, Silver PB, Chan CC, Sun B, Agarwal RK, Wells J et al (1996) Genetic susceptibility to experimental autoimmune uveoretinitis in the rat is associated with an elevated Th1 response. J Immunol 157(6):2668–2675

    CAS  PubMed  Google Scholar 

  44. Kim SJ, Zhang M, Vistica BP, Chan CC, Shen DF, Wawrousek EF et al (2002) Induction of ocular inflammation by T-helper lymphocytes type 2. Invest Ophthalmol Vis Sci 43(3):758–765

    PubMed  Google Scholar 

  45. McPherson SW, Yang J, Chan CC, Dou C, Gregerson DS (2003) Resting CD8 T cells recognize beta-galactosidase expressed in the immune-privileged retina and mediate autoimmune disease when activated. Immunology 110(3):386–396

    CAS  PubMed  Google Scholar 

  46. Song L, Le J, Ye F, Shao H, Kaplan HJ, Sun D (2008) Sequence 168 to 177 of interphotoreceptor retinoid-binding protein (IRBP) is an antigenic epitope for autoreactive CD8 T cells in the B10RIII mouse. J Neuroimmunol 193(1–2):68–76

    CAS  PubMed  Google Scholar 

  47. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR et al (1995) Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3(6):811–821

    CAS  PubMed  Google Scholar 

  48. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK et al (1995) Human IL-17: a novel cytokine derived from T cells. J Immunol 155(12):5483–5486

    CAS  PubMed  Google Scholar 

  49. Stockinger B, Veldhoen M, Martin B (2007) Th17 T cells: linking innate and adaptive immunity. Semin Immunol 19(6):353–361

    CAS  PubMed  Google Scholar 

  50. Ohta K, Wiggert B, Yamagami S, Taylor AW, Streilein JW (2000) Analysis of immunomodulatory activities of aqueous humor from eyes of mice with experimental autoimmune uveitis. J Immunol 164(3):1185–1192

    CAS  PubMed  Google Scholar 

  51. de Vos AF, van Haren MA, Verhagen C, Hoekzema R, Kijlstra A (1994) Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 35(3):1100–1106

    PubMed  Google Scholar 

  52. Planck SR, Huang XN, Robertson JE, Rosenbaum JT (1994) Cytokine mRNA levels in rat ocular tissues after systemic endotoxin treatment. Invest Ophthalmol Vis Sci 35(3):924–930

    CAS  PubMed  Google Scholar 

  53. Rizzo LV, Xu H, Chan CC, Wiggert B, Caspi RR (1998) IL-10 has a protective role in experimental autoimmune uveoretinitis. Int Immunol 10(6):807–814

    CAS  PubMed  Google Scholar 

  54. Saoudi A, Hurez V, de Kozak Y, Kuhn J, Kaveri SV, Kazatchkine MD et al (1993) Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 5(12):1559–1567

    CAS  PubMed  Google Scholar 

  55. MacPhee IA, Antoni FA, Mason DW (1989) Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J Exp Med 169(2):431–445

    CAS  PubMed  Google Scholar 

  56. O’Brien NC, Charlton B, Cowden WB, Willenborg DO (1999) Nitric oxide plays a critical role in the recovery of Lewis rats from experimental autoimmune encephalomyelitis and the maintenance of resistance to reinduction. J Immunol 163(12):6841–6847

    PubMed  Google Scholar 

  57. Lenz DC, Swanborg RH (1999) Suppressor cells in demyelinating disease: a new paradigm for the new millennium. J Neuroimmunol 100(1–2):53–57

    CAS  PubMed  Google Scholar 

  58. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z et al (2006) Foxp3 + CD25 + CD4 + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8–27

    CAS  PubMed  Google Scholar 

  59. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F (1999) An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190(7):995–1004

    CAS  PubMed Central  PubMed  Google Scholar 

  60. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK (2001) Type 1 T regulatory cells. Immunol Rev 182:68–79

    CAS  PubMed  Google Scholar 

  61. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155(3):1151–1164

    CAS  PubMed  Google Scholar 

  62. Ke Y, Jiang G, Sun D, Kaplan HJ, Shao H (2008) Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis. Invest Ophthalmol Vis Sci 49(9):3999–4007

    PubMed Central  PubMed  Google Scholar 

  63. Yamaki K, Tsuda M, Shinohara T (1988) The sequence of human retinal S-antigen reveals similarities with alpha-transducin. FEBS Lett 234(1):39–43

    CAS  PubMed  Google Scholar 

  64. Roberge FG, Lorberboum-Galski H, Le Hoang P, de Smet M, Chan CC, Fitzgerald D et al (1989) Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis. J Immunol 143(11):3498–3502

    CAS  PubMed  Google Scholar 

  65. Nussenblatt RB, Kuwabara T, de Monasterio FM, Wacker WB (1981) S-antigen uveitis in primates. A new model for human disease. Arch Ophthalmol 99(6):1090–1092

    CAS  PubMed  Google Scholar 

  66. Gregerson DS, Fling SP, Obritsch WF, Merryman CF, Donoso LA (1990) A new perspective of S-antigen from immunochemical analysis. Curr Eye Res 9(Suppl):145–153

    PubMed  Google Scholar 

  67. Donoso LA, Merryman CF, Sery TW, Vrabec T, Arbizo V, Fong SL, Human IRBP (1988) Characterization of uveitopathogenic sites. Curr Eye Res 7(11):1087–1095

    CAS  PubMed  Google Scholar 

  68. Kotake S, Redmond TM, Wiggert B, Vistica B, Sanui H, Chader GJ et al (1991) Unusual immunologic properties of the uveitogenic interphotoreceptor retinoid-binding protein-derived peptide R23. Invest Ophthalmol Vis Sci 32(7):2058–2064

    CAS  PubMed  Google Scholar 

  69. Pepperberg DR, Okajima TL, Ripps H, Chader GJ, Wiggert B (1991) Functional properties of interphotoreceptor retinoid-binding protein. Photochem Photobiol 54(6):1057–1060

    CAS  PubMed  Google Scholar 

  70. Wiggert B, Kutty G, Long KO, Inouye L, Gery I, Chader GJ et al (1991) Interphotoreceptor retinoid-binding protein (IRBP) in progressive rod-cone degeneration (prcd)–biochemical, immunocytochemical and immunologic studies. Exp Eye Res 53(3):389–398

    CAS  PubMed  Google Scholar 

  71. Lipham WJ, Sanui H, Redmond TM, Wiggert B, de Smet MD, Chader GJ et al (1990) Immunological features of synthetic peptides derived from the retinal protein IRBP: differences between immunodominant and non-dominant peptides. Curr Eye Res 9(1):95–98

    CAS  PubMed  Google Scholar 

  72. Hirose S, Wiggert B, Redmond TM, Kuwabara T, Nussenblatt RB, Chader GJ et al (1987) Uveitis induced in primates by IRBP: humoral and cellular immune responses. Exp Eye Res 45(5):695–702

    CAS  PubMed  Google Scholar 

  73. Eisenfeld AJ, Bunt-Milam AH, Saari JC (1987) Uveoretinitis in rabbits following immunization with interphotoreceptor retinoid-binding protein. Exp Eye Res 44(3):425–438

    CAS  PubMed  Google Scholar 

  74. Vistica BP, Usui M, Kuwabara T, Wiggert B, Lee L, Redmond TM et al (1987) IRBP from bovine retina is poorly uveitogenic in guinea pigs and is identical to A-antigen. Curr Eye Res 6(3):409–417

    CAS  PubMed  Google Scholar 

  75. Foster CSVA (2002) Diagnosis and treatment of uveitis. WB Saunders, Philadelphia

    Google Scholar 

  76. Stanbury RM, Graham EM (1998) Systemic corticosteroid therapy—side effects and their management. Br J Ophthalmol 82(6):704–708

    CAS  PubMed  Google Scholar 

  77. Heo J, Sepah YJ, Yohannan J, Renner M, Akhtar A, Gregory A et al (2012) The role of biologic agents in the management of non-infectious uveitis. Expert Opin Biol Ther 12(8):995–1008

    CAS  PubMed  Google Scholar 

  78. Giuliari GP, Hinkle DM, Foster CS (2009) Local treatment for lymphoid malignancies of the eye. Anticancer Agents Med Chem 9(10):1123–1128

    CAS  PubMed  Google Scholar 

  79. Pierreisnard A, Issa N, Barnetche T, Richez C, Schaeverbeke T (2012) Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Joint Bone Spine. doi:10.1016/j.jbspin.2012.09.023

    PubMed  Google Scholar 

  80. Brodszky V, Czirjak L, Geher P, Hodinka L, Karpati K, Pentek M et al (2007) Rituximab in patients with rheumatoid arthritis: systematic review. Orv Hetil 148(40):1883–1893

    PubMed  Google Scholar 

  81. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581

    CAS  PubMed  Google Scholar 

  82. Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H et al (2000) Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 84(1):107–109

    CAS  PubMed  Google Scholar 

  83. Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411–452

    CAS  PubMed  Google Scholar 

  84. Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296(5573):1634–1635

    CAS  PubMed  Google Scholar 

  85. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340(18):1398–1405

    CAS  PubMed  Google Scholar 

  86. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN et al (2006) Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 45(8):982–989

    CAS  Google Scholar 

  87. Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B et al (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 34(5):1146–1150

    CAS  PubMed  Google Scholar 

  88. Sharma SM, Ramanan AV, Riley P, Dick AD (2007) Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis 66(6):840–841

    CAS  PubMed  Google Scholar 

  89. Yue C, You X, Zhao L, Wang H, Tang F, Zhang F et al (2010) The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 30(12):1553–1557

    CAS  PubMed  Google Scholar 

  90. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M et al (2009) Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 36(4):801–808

    CAS  PubMed  Google Scholar 

  91. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4):253–259

    CAS  PubMed  Google Scholar 

  92. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S et al (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121(4):437–440

    CAS  PubMed  Google Scholar 

  93. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A (2005) Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 128(2):1047–1062

    Google Scholar 

  94. Galor A, Perez VL, Hammel JP, Lowder CY (2006) Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113(12):2317–2323

    PubMed  Google Scholar 

  95. Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56(10):3248–3252

    CAS  PubMed  Google Scholar 

  96. Neri P, Zucchi M, Allegri P, Lettieri M, Mariotti C, Giovannini A (2011) Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol 31(2):165–173

    PubMed  Google Scholar 

  97. Yeh S, Wroblewski K, Buggage R, Li Z, Kurup SK, Sen HN et al (2008) High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 31(2):91–97

    CAS  PubMed Central  PubMed  Google Scholar 

  98. Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, Van Veldhuisen P et al (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 96(13):7462–7466

    CAS  PubMed  Google Scholar 

  99. Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See RF, Letko E et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112(5):764–770

    PubMed  Google Scholar 

  100. Hernandez Garfella ML, Diaz Llopis M, Salom Alonso D, Cervera TauletE (2004) Recurrent uveitis and therapy with monoclonal antibody (daclizumab). Arch Soc Esp Oftalmol 79(12):593–598

    CAS  PubMed  Google Scholar 

  101. Planck SR, Woods A, Clowers JS, Nicklin MJ, Rosenbaum JT, Rosenzweig HL (2012) Impact of IL-1 signalling on experimental uveitis and arthritis. Ann Rheum Dis 71(5):753–760

    CAS  PubMed Central  PubMed  Google Scholar 

  102. Teoh SC, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD (2007) Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 91(2):263–264

    CAS  PubMed  Google Scholar 

  103. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J (2005) Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 102(9):3372–3377

    CAS  PubMed  Google Scholar 

  104. Plskova J, Greiner K, Muckersie E, Duncan L, Forrester JV (2006) Interferon-alpha: a key factor in autoimmune disease? Invest Ophthalmol Vis Sci 47(9):3946–3950

    PubMed  Google Scholar 

  105. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D et al (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10(13):4025–4031

    CAS  PubMed  Google Scholar 

  106. Rosenbaum JT, Howes EL Jr, Rubin RM, Samples JR (1988) Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol 133(1):47–53

    CAS  PubMed  Google Scholar 

  107. Dick AD, McMenamin PG, Korner H, Scallon BJ, Ghrayeb J, Forrester JV et al (1996) Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol 26(5):1018–1025

    CAS  PubMed  Google Scholar 

  108. Sartani G, Silver PB, Rizzo LV, Chan CC, Wiggert B, Mastorakos G et al (1996) Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci 37(11):2211–2218

    CAS  PubMed  Google Scholar 

  109. Nakamura S, Yamakawa T, Sugita M, Kijima M, Ishioka M, Tanaka S et al (1994) The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci 35(11):3884–3889

    CAS  PubMed  Google Scholar 

  110. Korner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD (1997) Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 186(9):1585–1590

    CAS  PubMed Central  PubMed  Google Scholar 

  111. Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J (1998) Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun 11(3):255–264

    CAS  PubMed  Google Scholar 

  112. Robertson M, Liversidge J, Forrester JV, Dick AD (2003) Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 44(7):3034–3041

    PubMed  Google Scholar 

  113. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J et al (1998) TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 4(1):78–83

    CAS  PubMed  Google Scholar 

  114. Demir T, Godekmerdan A, Balbaba M, Turkcuoglu P, Ilhan F, Demir N (2006) The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis. Indian J Ophthalmol 54(4):241–245

    PubMed  Google Scholar 

  115. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN (1996) Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 39(7):1082–1091

    CAS  PubMed  Google Scholar 

  116. Mo JS, Matsukawa A, Ohkawara S, Yoshinaga M (1998) Involvement of TNF alpha, IL-1 beta and IL-1 receptor antagonist in LPS-induced rabbit uveitis. Exp Eye Res 66(5):547–557

    CAS  PubMed  Google Scholar 

  117. de Kozak Y, Verwaerde C (2002) Cytokines in immunotherapy of experimental uveitis. Int Rev Immunol 21(2–3):231–253

    PubMed  Google Scholar 

  118. Guex-Crosier Y, Raber J, Chan CC, Kriete MS, Benichou J, Pilson RS et al (1997) Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 158(1):452–458

    CAS  PubMed  Google Scholar 

  119. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T (1998) Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 20(1–2):247–259

    CAS  PubMed  Google Scholar 

  120. Ohta K, Yamagami S, Taylor AW, Streilein JW (2000) IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 41(9):2591–2599

    CAS  PubMed  Google Scholar 

  121. Rosenbaum JT, Kievit P, Han YB, Park JM, Planck SR (1998) Interleukin-6 does not mediate endotoxin-induced uveitis in mice: studies in gene deletion animals. Invest Ophthalmol Vis Sci 39(1):64–69

    CAS  PubMed  Google Scholar 

  122. Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR (1998) Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. J Immunol 161(1):122–127

    CAS  PubMed  Google Scholar 

  123. Yokoi H, Kato K, Kezuka T, Sakai J, Usui M, Yagita H et al (1997) Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12. Eur J Immunol 27(3):641–646

    CAS  PubMed  Google Scholar 

  124. Okamoto S, Streilein JW (1998) Role of inflammatory cytokines in induction of anterior chamber-associated immune deviation. Ocul Immunol Inflamm 6(1):1–11

    CAS  PubMed  Google Scholar 

  125. Li Q, Sun B, Dastgheib K, Chan CC (1996) Suppressive effect of transforming growth factor beta1 on the recurrence of experimental melanin protein-induced uveitis: upregulation of ocular interleukin-10. Clin Immunol Immunopathol 81(1):55–61

    CAS  PubMed  Google Scholar 

  126. Vinores SA, Chan CC, Vinores MA, Matteson DM, Chen YS, Klein DA et al (1998) Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol 89(1–2):43–50

    CAS  PubMed  Google Scholar 

  127. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS et al (1994) Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 180(5):1961–1966

    CAS  PubMed  Google Scholar 

  128. Ramanathan S, de Kozak Y, Saoudi A, Goureau O, Van der Meide PH, Druet P et al (1996) Recombinant IL-4 aggravates experimental autoimmune uveoretinitis in rats. J Immunol 157(5):2209–2215

    CAS  PubMed  Google Scholar 

  129. Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M et al (1993) Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362(6417):248–250

    CAS  PubMed  Google Scholar 

  130. Marie O, Thillaye-Goldenberg B, Naud MC, de Kozak Y (1999) Inhibition of endotoxin-induced uveitis and potentiation of local TNF-alpha and interleukin-6 mRNA expression by interleukin-13. Invest Ophthalmol Vis Sci 40(10):2275–2282

    CAS  PubMed  Google Scholar 

  131. Lemaitre C, Thillaye-Goldenberg B, Naud MC, de Kozak Y (2001) The effects of intraocular injection of interleukin-13 on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 42(9):2022–2030

    CAS  PubMed  Google Scholar 

  132. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765

    CAS  PubMed  Google Scholar 

  133. Okada AA, Sakai J, Usui M, Mizuguchi J (1998) Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 6(2):111–120

    CAS  PubMed  Google Scholar 

  134. Sun B, Sun SH, Chan CC, Caspi RR (2000) Evaluation of in vivo cytokine expression in EAU-susceptible and resistant rats: a role for IL-10 in resistance? Exp Eye Res 70(4):493–502

    CAS  PubMed  Google Scholar 

  135. Gao Y, Herndon JM, Zhang H, Griffith TS, Ferguson TA (1998) Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis. J Exp Med 188(5):887–896

    CAS  PubMed Central  PubMed  Google Scholar 

  136. Calder VL, Shaer B, Muhaya M, Mclauchlan M, Pearson RV, Jolly G et al (1999) Increased CD4 + expression and decreased IL-10 in the anterior chamber in idiopathic uveitis. Invest Ophthalmol Vis Sci 40(9):2019–2024

    CAS  PubMed  Google Scholar 

  137. Rosenbaum JT, Angell E (1995) Paradoxical effects of IL-10 in endotoxin-induced uveitis. J Immunol 155(8):4090–4094

    CAS  PubMed  Google Scholar 

  138. Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgensen C (1998) Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 160(11):5213–5220

    CAS  PubMed  Google Scholar 

  139. Lechman ER, Jaffurs D, Ghivizzani SC, Gambotto A, Kovesdi I, Mi Z et al (1999) Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol 163(4):2202–2208

    CAS  PubMed  Google Scholar 

  140. Cua DJ, Hutchins B, LaFace DM, Stohlman SA, Coffman RL (2001) Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J Immunol 166(1):602–608

    CAS  PubMed  Google Scholar 

  141. Croxford JL, Feldmann M, Chernajovsky Y, Baker D (2001) Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J Immunol 166(6):4124–4130

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

No funding support to disclose/no proprietary or financial interest to disclose.

Author information

Authors and Affiliations

  1. Centro de Cirugía Oftalmológica (CECOF), Caracas, Venezuela

    Gian Paolo Giuliari

  2. Department of Ophthalmology, School of Medicine, Domingo Luciani Hospital, Universidad Central de Venezuela, Caracas, Venezuela

    Gian Paolo Giuliari

  3. Trihealth’s Good Samaritan Hospital, Cincinnati, OH, USA

    Ama Sadaka

  4. Albany Retina Consultants PLLC, Slingerlands, NY, 12159, USA

    David M. Hinkle

  5. Av. Francisco de Miranda, Torre Cavendes, Piso 6, Ofic. 6-04, Altamira, Caracas, Venezuela

    Gian Paolo Giuliari

Authors
  1. Gian Paolo Giuliari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ama Sadaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David M. Hinkle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gian Paolo Giuliari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giuliari, G.P., Sadaka, A. & Hinkle, D.M. Biologic agents in experimental autoimmune uveitis. Int Ophthalmol 34, 145–156 (2014). https://doi.org/10.1007/s10792-013-9756-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-013-9756-0

Keywords

Search

Navigation